Apellis Pharmaceuticals on Friday announced positive Year 1 results from the Phase 2 NOBLE study investigating systemic pegcetacoplan, a targeted C3 therapy, for the treatment of post-transplant recurrence of C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis, demonstrating a persistence of effect, Stifel tells investors in a research note. The results reaffirm the firm’s confidence ahead of the readout of the pivotal Phase 3 VALIANT trial, which is underway with topline results expected in mid-2024, the firm says. Stifel made no change to its Buy rating.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress
- Apellis price target lowered to $48 from $57 at Wells Fargo
- 3 Best Stocks to Buy Now, 5/15/2024, According to Top Analysts
- Apellis refinances existing debt with up to $475M credit facility
- Apellis price target lowered to $60 from $67 at Citi